Versican Plus Pi

RSS

canine parainfluenza virus

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 16/05/2019

Authorisation details

Product details
Name
Versican Plus Pi
Agency product number
EMEA/V/C/003681
Active substance
canine parainfluenza type-2 virus, strain CPiV-2 Bio 15 (live attenuated)
International non-proprietary name (INN) or common name
canine parainfluenza virus
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI07AD08
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
03/07/2014
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

17/04/2019 Versican Plus Pi - EMEA/V/C/003681 - IB/0012

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for canidae

  • Live viral vaccines

Therapeutic indication

Active immunisation of dogs from six weeks of age to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus.

Assessment history

How useful was this page?

Add your rating